CompletedPhase 3

LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)

France107 participantsStarted 2011-10-27

Plain-language summary

The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.

Who can participate

Age range5 Years – 71 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * P53 mutation

What they're measuring

cancer incidence

Timeframe: 3 years

Trial details

NCT IDNCT01464086

SponsorGustave Roussy, Cancer Campus, Grand Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-03-31

View on ClinicalTrials.gov More Li Fraumeni Syndrome trials